Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Moodys
Medtronic
Express Scripts
Boehringer Ingelheim

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HEPARIN CALCIUM

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Heparin Calcium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000472 Thrombolysis in Myocardial Ischemia Trial (TIMI III) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1989-04-01 The Thrombolysis in Myocardial Ischemia Trial (TIMI III) focused on unstable angina and non-Q-wave myocardial infarction. The trial was designed to determine by coronary arteriography the incidence of coronary thrombi in these conditions and the response of these thrombi to tissue-type plasminogen activator (t-PA) in TIMI IIIA and the effects of thrombolytic therapy and of an early invasive strategy on clinical outcome in TIMI IIIB. There was also a registry with two components. A roster enumerated all patients with unstable angina or non-Q-wave myocardial infarction enrolled at cooperating hospitals. From the roster, a study population of 1,893 subjects was selected and followed prospectively for the year to determine incidence of death or myocardial infarction.
NCT00000473 Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty? Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1989-07-01 To determine whether a dietary supplement of n-3 polyunsaturated fatty acids (PUFAs) derived from fish oil would decrease the restenosis rate in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
NCT00004786 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed University of Pittsburgh Phase 3 1995-12-01 OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
NCT00004786 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed National Center for Research Resources (NCRR) Phase 3 1995-12-01 OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
NCT00212043 Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed Eli Lilly and Company Phase 2 2000-07-01 Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
NCT00212043 Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma Completed National University Hospital, Singapore Phase 2 2000-07-01 Hypothesis - Infusional gemcitabine may give better intracellular pharmacologic activation and be more effective clinically in non-small cell lung cancer
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Heparin Calcium

Condition Name

Condition Name for Heparin Calcium
Intervention Trials
Coronary Disease 2
Myocardial Ischemia 2
Cardiovascular Diseases 2
Heart Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Heparin Calcium
Intervention Trials
Kidney Diseases 3
Cardiovascular Diseases 3
Ischemia 2
Proteinuria 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Heparin Calcium

Trials by Country

Trials by Country for Heparin Calcium
Location Trials
Spain 9
Italy 9
United States 4
Korea, Republic of 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Heparin Calcium
Location Trials
Tennessee 1
Ohio 1
Virginia 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Heparin Calcium

Clinical Trial Phase

Clinical Trial Phase for Heparin Calcium
Clinical Trial Phase Trials
Phase 4 3
Phase 3 8
Phase 2 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Heparin Calcium
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 5
Recruiting 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Heparin Calcium

Sponsor Name

Sponsor Name for Heparin Calcium
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 2
National University Hospital, Singapore 2
University of Pittsburgh 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Heparin Calcium
Sponsor Trials
Other 24
NIH 4
Industry 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Baxter
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.